Search results
Results from the WOW.Com Content Network
A recent study by the National Center for Health Statistics revealed that a higher percentage of women 20 and older have high total cholesterol than men in the same age group, and the rates ...
Statins appear to be effective at preventing cardiovascular disease and death in older adults, according to new research. Most clinical trials evaluating statins have not included people 75 and ...
Statins “help reduce the risk of plaque ruptures and stabilize the blood vessels” in addition to reducing cholesterol, Serwer says. These medications are a “first-line therapy, after diet ...
A risk exists of muscle damage (myopathy and rhabdomyolysis) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85. [2] Fibrates are indicated for hypertriglyceridemia. Fibrates typically lower triglycerides by 20% to 50%.
In those at intermediate risk or low risk, the use of statin therapy depends on individual patient factors such as age, cholesterol levels, and risk factors. [4] Statins are considered the first-line agents but other drugs can be substituted if the lipid targets are not achieved with statin therapy or if they are not tolerated. [4] [14] [15]
Use during pregnancy may harm the baby. [6] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol. [6] Rosuvastatin was patented in 1991 and approved for medical use in the United States in 2003. [6] [7] It is available as a generic medication. [6]
After an eight-week trial, adults at-risk for cardiovascular disease who ate pecans every day demonstrated a reduction—between 6% and 9% —in LDL cholesterol, as well as triglyceride levels ...
Cerivastatin (INN, [1] brand names: Baycol, Lipobay) is a synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease.It was marketed by the pharmaceutical company Bayer A.G. in the late 1990s, competing with Pfizer's highly successful atorvastatin (Lipitor).